Silence Therapeutics (SLN) Total Liabilities (2024 - 2026)

Silence Therapeutics (SLN) has 3 years of Total Liabilities data on file, last reported at $65.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 9.42% year-over-year to $65.7 million; the trailing twelve-month figure through Mar 2026 stood at $65.7 million (down 9.42% YoY), and the FY2025 full-year result was $69.1 million, up 0.77% from the prior year.
• Total Liabilities declined to $65.7 million in Q1 2026, from $69.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $72.7 million in Q3 2025 to a low of $65.7 million in Q1 2026.
• A 3-year average of $70.0 million and a median of $70.1 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities rose 0.77% in 2025 and decreased 9.42% in 2026, its largest moves.
• Tracing SLN's Total Liabilities over 3 years: stood at $68.6 million in 2024, then advanced by 0.77% to $69.1 million in 2025, then retreated by 4.94% to $65.7 million in 2026.
• Business Quant data shows SLN's Total Liabilities at $65.7 million in Q1 2026, $69.1 million in Q4 2025, and $72.7 million in Q3 2025.